RT Journal Article
SR Electronic
T1 ON THE UNCERTAINTY ABOUT HERD IMMUNITY LEVELS REQUIRED TO STOP COVID-19 EPIDEMICS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.31.20118695
DO 10.1101/2020.05.31.20118695
A1 Gianola, Daniel
YR 2020
UL http://medrxiv.org/content/early/2020/06/01/2020.05.31.20118695.abstract
AB COVID-19 evolved into a pandemic in 2020 affecting more than 150 countries. Given the absence of a vaccine, discussion has taken place on the strategy of allowing the virus to spread in a population, to increase population “herd immunity”. Knowledge of the minimum proportion of a population required to have recovered from COVID-19 infection in order to attain “herd” immunity, Pcrit, is important for formulating epidemiological policy. A method for measuring uncertainty about Pcrit based on a widely used package, EpiEstim, is derived. The procedure is illustrated using data from twelve countries at two early times during the COVID-19 epidemic. It is shown that simple plug-in measures of confidence on estimates of Pcrit are misleading, but that a full characterization of statistical uncertainty can be derived from EpiEstim, which reports percentiles only. Because of the important levels of uncertainty, it is risky to design epidemiological policy based on guidance provided by a single point estimate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNONEAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-geographic-disbtribution-worldwide https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-geographic-disbtribution-worldwide